Quick Answer
Lineage Cell Therapeutics, Inc. reported Shares Outstanding of 243.12 million shares for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 243.12M | +10.3% |
| 2024 | 220.42M | +26.0% |
| 2023 | 174.99M | +2.9% |
| 2022 | 170.09M | +0.4% |
| 2021 | 169.48M | +10.7% |
| 2020 | 153.10M | +2.2% |
| 2019 | 149.80M | +17.8% |
| 2018 | 127.14M | +0.2% |
| 2017 | 126.87M | +23.4% |
| 2016 | 102.78M | +13.7% |
| 2015 | 90.42M | +15.6% |
| 2014 | 78.23M | +37.9% |
| 2013 | 56.71M | +14.8% |
| 2012 | 49.38M | +0.7% |
| 2011 | 49.04M | +2.6% |
| 2010 | 47.78M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 230.33M | +22.0% | +0.9% |
| June 30, 2025 | 228.36M | +20.9% | +0.0% |
| March 31, 2025 | 228.36M | +21.0% | +3.6% |
| December 31, 2024 | 220.42M | +26.0% | +16.7% |
| September 30, 2024 | 188.84M | +7.9% | +0.0% |
| June 30, 2024 | 188.82M | +8.2% | +0.0% |
| March 31, 2024 | 188.75M | +10.9% | +7.9% |
| December 31, 2023 | 174.99M | +2.9% | +0.0% |
- Lineage Cell Therapeutics, Inc. showed an increase of +10.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2010–2025 period, Lineage Cell Therapeutics, Inc.’s shares outstanding has grown by 408.9% (from 47.78 million shares to 243.12 million shares).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: